OVARIAN BRENNER TUMOR
Clinical trials for OVARIAN BRENNER TUMOR explained in plain language.
Never miss a new study
Get alerted when new OVARIAN BRENNER TUMOR trials appear
Sign up with your email to follow new studies for OVARIAN BRENNER TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Weekly vs. Every-3-Weeks chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 patients with advanced ovarian, peritoneal, or fallopian tube cancer. The goal w…
Matched conditions: OVARIAN BRENNER TUMOR
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Matched conditions: OVARIAN BRENNER TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Matched conditions: OVARIAN BRENNER TUMOR
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC